Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific
Thymoma
Explore 1 assets in Thymoma →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Xencor, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03517488CT.gov A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Thymoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific (this asset) | Xencor, Inc. | P1 | CC · 47 |
| Avelumab | National Cancer Institute (NCI) | P2 | CCC |
| Bosutinib | Nagla Abdel Karim | P1 | CC |
| Palifosfamide-Tris | Alaunos Therapeutics | P1 | CC |
| Doxepin | Mayo Clinic | P2 | C |
Other indications for Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuroendocrine Carcinoma | — | P2 | B · 57 |
| High Grade Malignant Neoplasm | — | P2 | CCC · 53 |
| Peritoneal Mesothelioma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific in Thymoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-half-ig-g1-kappascfv-h-ch2-ch3-anti-homo-sapiens-ctla4-cytotoxic-t-lymphocyte-associated-protein-4-cd152-and-anti-homo-sapienspdcd1-programmed-cell-death-1-pd-1-pd1-cd279-monoclonal-antibody-bispecific-thymoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →